During Tuesday’s Current trade, Shares of PMC-Sierra Inc (NASDAQ:PMCS), lost -1.11% to $6.22.
PMC-Sierra, Inc. (PMCS), the semiconductor and software solutions innovator transforming netoperates that connect, move and store big data, recently stated results for the second quarter ended June 27, 2015.
Net revenues in the second quarter of 2015 totaled $124.8 million, a decrease of 1.6 percent, contrast to $126.8 million in the second quarter of 2014, and a decrease of 6.2 percent from $133.1 million in the first quarter of 2015.
GAAP net loss in the second quarter of 2015 totaled $8.6 million or $0.04 per share, contrast to GAAP net loss in the second quarter of 2014 of $3.5 million or $0.02 per share, and GAAP net income in the first quarter of 2015 of $4.7 million or $0.02 per diluted share.
Non-GAAP net income in the second quarter of 2015 totaled $18.0 million or $0.09 per diluted share, contrast to non-GAAP net income in the second quarter of 2014 of $18.3 million or $0.09 per diluted share, and to non-GAAP net income in the first quarter of 2015 of $20.9 million or $0.10 per diluted share.
PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, counting storage, optical, and mobile netoperates.
Shares of Dreamoperates Animation Skg Inc (NASDAQ:DWA), declined -1.33% to $19.67, during its current trading session.
Dreamworks Animation Skg Inc (DWA) has found a very real director for the story of an imaginary friend, as the Academy Award-nominated Jason Reitman is set to write and direct “Beekle,” based on the award-winning children’s book, “The Adventures of Beekle: The Unimaginary Friend.
Beekle is the first project to be put into development by DreamWorks Animation’s recently designated Co-Presidents of Feature Animation Bonnie Arnold and Mireille Soria. It is the first foray into animation for Reitman, the celebrated director of films counting the Academy Award-nominated “Juno,” “Thank You For Smoking,” “Young Adult,” “Labor Day,” “Men, Women & Children,” and the Academy Award-nominated “Up in the Air,” for which Reitman earned a Golden Globe Award for Best Screenplay. Written and illustrated by Dan Santat, “The Adventures of Beekle: The Unimaginary Friend,” is the 2015 recipient of the prestigious Caldecott Medal, awarded annually to the most distinguished American picture book for children.
DreamWorks Animation development executive Damon Ross brought the project to the studio, which he, together with the studio’s Head of Development Gregg Taylor are overseeing.
DreamWorks Animation SKG, Inc. engages in the development, production, and exploitation of animated films and their associated characters worldwide. The company operates in four segments: Feature Films, Television Series and Specials, Consumer Products, and New Media. It creates and exploits family entertainment, counting animated feature films, television series and specials, live entertainment properties, and related consumer products, in addition to licenses distribution rights.
Real Goods Solar, Inc. - Class A (NASDAQ:RGSE), during its Tuesday’s current trading session gained 0.82% to $1.26.
RGS Energy (RGSE), one of the nation’s leading rooftop installers of solar equipment, has received notification from The Nasdaq Stock Market LLC (“NASDAQ”) that it has regained compliance with NASDAQ Marketplace Rules.
As formerly declared, on April 14, 2015, NASDAQ notified the company that it was no longer in compliance with NASDAQ Listing Rule 5550(b)(2) because the minimum Market Value of Listed Securities (MVLS) of the company’s Class A common stock had fallen below $35 million for the 30 business day period between February 24, 2015 and April 13, 2015, and describing a 180 day timetable for bringing the company into compliance with that rule.
Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction company in the United States. It operates in three segments: Residential, Sunetric, and Other. The company offers solar energy services, counting design, procurement, permitting, build-out, grid connection, financing referrals, and warranty and customer satisfaction. It installs residential solar energy systems up to 15 kilowatts (kW) output; and small commercial solar energy systems up to 200 kW output for various industries, such as retail, manufacturing, service, and municipal services.
Finally, Amgen, Inc. (NASDAQ:AMGN), decreased -1.65%, to $149.50.
Amgen (AMGN) declared positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of AMG 334 for the prevention of episodic migraine. Patients who entered the open-label phase received AMG 334 70 mg monthly and practiced a sustained reduction in monthly migraine days at week 52.
At one year, patients receiving AMG 334 70 mg practiced an average of a -4.9-day reduction from a baseline of 8.7 mean monthly migraine days, regardless of treatment received during the blinded phase. The 50 percent responder rate (greater than 50 percent reduction in monthly migraine days) was 62 percent at 52 weeks. Additional responder rates were stated for the first time: at 52 weeks the 75 percent responder rate was 38 percent and the 100 percent responder rate was 19 percent.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products comprise Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
